Evidence map›Paper›PMID 20981002›Full record

ReviewClinical pharmacology and therapeutics2010

Breaking barriers in the genomics and pharmacogenetics of drug addiction.

M K Ho, D Goldman, A Heinz, J Kaprio, M J Kreek, M D Li, M R Munafò, R F Tyndale

Abstract readReview
In one paragraph

Review in Clinical pharmacology and therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Candidate gene studies of a promising intermediate phenotype: failure to replicate.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013
    Trial
  3. Trial
  4. Article
  5. Paternal heroin self-administration in rats increases drug-seeking behavior in male offspring via miR-19b downregulation in the nucleus accumbens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  6. Article
  7. bioRxiv : the preprint server for biology · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Genetic Polymorphism in the Promoter Region of Serotonin Transporter: Implications for Ethanol Abuse in Children and Adolescents.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 5 countries.

M K HoCentre for Addiction & Mental Health, Department of Psychiatry, Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
D Goldman
A Heinz
J Kaprio
M J Kreek
M D Li
M R Munafò
R F Tyndale
Centre for Addiction and Mental Health · CACharité - Universitätsmedizin Berlin · DENational Institutes of Health · USRockefeller University · USUniversity of Bristol · GBUniversity of Helsinki · FIUniversity of Virginia · US

Funding

Integrative genetics of behavior with high throughput technologiesZIAAA000301 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI GOLDMAN, DAVID · 2009 to 2025
$68.6M
TRANSFORMING TRANSLATIONAL SCIENCE AND EDUCATION TO BENEFIT HUMAN HEALTHUL1RR024143 · NCRR · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2006 to 2011
$49.1M
ULTRASTUCTURE, RECEPTORS, AND GENE EXPRESSIONP60DA005130 · NIDA · ROCKEFELLER UNIVERSITY · PI KREEK, MARY J · 2002 to 2012
$30.6M
University of Toronto Coordinating Genetics Core & Clinical Trial SiteU01DA020830 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI SWAN, GARY E · 2005 to 2014
$22.4M
THE GENETICS OF VULNERABILITY TO NICOTINE ADDICTIONSR01DA012854 · NIDA · WASHINGTON UNIVERSITY · PI MADDEN, PAMELA ANN · 2000 to 2013
$10.4M
MAPPING OF SUSCEPTIBILITY LOCI FOR NICOTINE DEPENDENCER01DA012844 · NIDA · UNIVERSITY OF VIRGINIA · PI LI, MING D · 1999 to 2013
$10.0M
UNIQUE RNA STRUCTURE OF CAUSATIVE AGENT FOR DELTA HEPATITISP50DA005130 · NIDA · ROCKEFELLER UNIVERSITY · PI KREEK, MARY J · 1987 to 2001
$5.0M
GENE EXPRESSION PROFILING DURING EXPOSURE TO NICOTINER01DA013783 · NIDA · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LI, MING D · 2000 to 2008
$3.9M
HIV and Psychiatric Comorbidity: Selected Genetic and Epigenetic FactorsR01MH079880 · NIMH · ROCKEFELLER UNIVERSITY · PI KREEK, MARY J · 2006 to 2010
$3.0M
Substance Abuse and HIV: Genetics &Disease ProgressionR01MH076537 · NIMH · SUNY DOWNSTATE MEDICAL CENTER · PI CRYSTAL, HOWARD A · 2005 to 2009
$2.2M
ALCOHOL AND MENTAL DISORDERS IN ED TREATED ADOLESCENTSK08AA000280 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KELLY, THOMAS M · 2000 to 2004
$562k
Intermediate Phenotypes for Alcoholism &AnxietyZ01AA000280 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI GOLDMAN, DAVID · 1990 to 2008
$491k
CIHR MOP86471Intramural NIH HHS Z01 AA000280NCRR NIH HHS UL1 RR024143NIAAA NIH HHS K08 AA000280NIDA NIH HHS DA012844NIDA NIH HHS DA012854NIDA NIH HHS DA013783NIDA NIH HHS DA 0220830NIDA NIH HHS P50 DA005130NIDA NIH HHS P60 DA005130NIDA NIH HHS P60-DA005130NIDA NIH HHS R01 DA012844NIDA NIH HHS R01 DA012854NIDA NIH HHS R01 DA013783NIDA NIH HHS R56 DA012854NIDA NIH HHS U01 DA020830NIMH NIH HHS R01 MH076537NIMH NIH HHS R01 MH079880NIMH NIH HHS R01-MH79880NIMH NIH HHS R21 MH097639
6 · The paper itself

Abstract

Drug addiction remains a substantial health issue with limited treatment options currently available. Despite considerable advances in the understanding of human genetic architecture, the genetic underpinning of complex disorders remains elusive. On the basis of our current understanding of neurobiology, numerous candidate genes have been implicated in the etiology and response to treatment for different addictions. Genome-wide association (GWA) studies have also identified novel targets. However, replication of these studies is often lacking, and this complicates interpretation. The situation is expected to improve as issues such as phenotypic characterization, the apparent "missing heritability," the identification of functional variants, and possible gene-environment (G × E) interactions are addressed. In addition, there is growing evidence that genetic information can be useful in refining the choice of addiction treatment. As genetic testing becomes more common in the practice of medicine, a variety of ethical and practical challenges, some of which are unique to drug addiction, will also need to be considered.

Indexed as

Genetic TestingGenetic VariationGenomicsHumansMethadoneNaltrexonePharmacogeneticsSubstance-Related DisordersMethadoneNaltrexone

Identifiers

PMID20981002
PMCPMC3738009
OpenAlexW1992517458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.